Introduction
It has been over a decade since the identi®cation of the Id protein family, and to paraphrase a familiar phrase, Id's come a long way baby'. Originally identi®ed as dominant negative antagonists of the basic helix ± loop ± helix transcription factor family, as described within this review other key cell cycle regulatory and transcription factors may be under Id control thus expanding its sphere of in¯uence signi®cantly. In addition to roles in normal developmental processes, strong genetic and cell biological data suggest that Id may play a crucial role in tumor progression and in the formation of blood vessels that support their growth.
Three sets of proteins have been identi®ed most convincingly as being primary targets for the Id proteins: the ubiquitously expressed basic helix ± loop ± helix (bHLH) E-protein family, Rb and Ets family members. Genetic, reverse genetic and biochemical data all suggest interactions of various Id family members with these proteins in certain cell types at certain times. Id proteins interact avidly with Eproteins in vitro and in vivo and inhibit their binding to DNA and other members of the bHLH family. Loss of E2A proteins is partially compensated by loss of Id1 and over expression of Id inhibits E-protein mediated transcription activation consistent with E-proteins being a primary cellular target for Id. Since E-proteins are obligate partners for tissue speci®c bHLH proteins, this allows for a common biochemical mechanism to regulate the transcription and cell fate decisions in multiple cell types. More recently, strong genetic data support the notion that Id2 is restrained by Rb family members since phenotypes in Rb null embryos are partially surprised by loss of Id2. In addition, it has been shown that Id2 is required for myc mediated transformation as myc directly activates the Id2 enhancer and loss of Id2 blocks myc mediated transformation. Finally, while control of p16 by Id1,3 was suggested from the analysis of Id1,3 knockout mice which display elevated levels of p16, the work of E Hara and colleagues demonstrate that this eect is being mediated by an interaction of Id1 with Ets proteins which transactivate the p16 enhancer.
But all these interactions may not be in separate pathways. For example loss of Rb, which leads to the deregulation of Id2, may be eectively causing the sequestration and inactivation of the growth suppressive E-proteins. This hypothesis predicts that loss of Rb might be rescued by supplying more E-proteins, a testable hypothesis. In addition, sequestration of Ets proteins by Id1 leads to a down regulation of p16, which may in turn lead to the hyperphosphorylation of Rb and therefore an increase in the eective concentration of Id2. It is the understanding of this type of cross talk between pathways that is now the challenge, which if met, will provide a more comprehensive view of this family of proteins.
This issue features an outstanding collection of articles that focus on the role of Id and other negative regulators of the bHLH family in a wide variety of systems. We begin with a review of the role of Id in early development by Y Yokota. In addition to con®rming some of the functions of the Id family predicted from cell culture analysis, genetically modi®ed animals have revealed functional redundancy of the Id proteins and a requirement for these proteins in unexpected organs and cell types. The analysis of the Id orthologue extramacrochaete (emc) by Campuzano also reveals some surprises in its regulation of developmental processes other than sensory organ development in which the function of emc was initially characterized. That emc can act as a positive regulator of dierentiation, has been observed in Drosophila and higher organisms and points to the fact that the negative regulation of transcription factors can have a positive or negative eect on dierentiation status depending on cell type.
In a sense the purest cell fate decision under Id control may be in the lymphocyte lineage, where the target of the Id proteins are likely to be E-protein homodimers by themselves. The eects of loss of the Id proteins and over expression experiments are reviewed in the section by Rivera and Murre. The connection between the Ras/Map kinase pathways and Id expression, suggested by the similarity in altered thymocyte maturation in Id3 de®cient mice compared to mice expressing dominant negative forms of MEK-1 or mice lacking ERK1, is also explored in this section of the review.
The next three sections of this issue provide a link between the theoretical and practical aspects of Id biology as it relates to tumorigenesis. Perturbations in dierentiation and cell cycle as well as the vascularization of tumors have all been shown to be important components of tumorigenesis. Id proteins remarkably have been placed in the middle of all of these pathways. In the chapter by Zebedee and Hara, the role of the Id proteins in the regulation of Rb and Ets family members is explored and identi®es Id as a critical negative regulator of the Rb arm of tumor suppression. A Lasorella et al. review the deregulated expression of the Ids during tumorigenesis and their likely role in the development and progression of various neoplasias. Notably Id2 is identi®ed as a critical mediator of myc mediated transformation which opens an exciting link between two dierent bHLH transcription factor family members. Finally Benezra et al. describe the requirement of Id1 and Id3 proteins in the development of neovasculature in tumors. Importantly these proteins do not seem to be required for normal adult vascularization, a property not shared with other factors currently being targeted in anti-angiogenesis therapies. Practically then, there is good reason to suspect that the inhibition of all of the Ids in adults may both inhibit the growth of certain tumors as well as their blood supply, a combination therapy that is likely to have a more dramatic eect on tumor growth than either approach alone.
Finally, in the last section, Davis and Turner remind us that Ids are not alone in their negative regulation of the bHLH family. They provide a comprehensive review of hairy, Enhancer of split family of bHLH proteins (containing a conserved orange domain) which act principally as active antagonists of transcription by binding to speci®c DNA sequences and recruiting corepressors to inhibit transcriptional activation. Importantly, this family has been shown to play critical roles in the Notch signaling pathway, neurogenesis, vaculogenesis, mesoderm segmentation and muscle development.
Together then it is hoped that the review articles in this issue of Oncogene will provide a useful reference to the molecular and cancer biologists who wish to explore this exciting class of molecules. As can be seen in this issue, the hope of weaving together developmental and cell biological signaling with the onset and progression of tumor growth has been realized in the analysis of the Id family and its relatives. Proof again that sound basic biology often leads to a deeper understanding of disease. If targeting these proteins can ultimately lead to a therapeutic intervention, a complete and most satisfying circle will have been drawn.
